Jones Trading Initiates Coverage On Beam Therapeutics With Hold Rating
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Hold Rating
JonesTrading analyst Soumit Roy initiates coverage on $Beam Therapeutics(BEAM.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 23.5% and a total average return
Hold Rating on Beam Therapeutics Amid Competitive Pressure and Absence of Clinical Data
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $69
Stifel analyst Dae Gon Ha maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and adjusts the target price from $66 to $69.According to TipRanks data, the analyst has a success rate of 46.0%
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $69
Stifel analyst Benjamin Burnett maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and adjusts the target price from $103 to $69.According to TipRanks data, the analyst has a success rate of 35
Beam Therapeutics Is Maintained at Buy by Stifel
Express News | Beam Therapeutics Inc : Stifel Raises Target Price to $69 From $66
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
H.C. Wainwright analyst Patrick Trucchio maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 3
Optimistic Outlook on Beam Therapeutics: Advancements and Potential in Precision Genetic Medicines
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine With CRISPR Technology
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases
Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
Beam Therapeutics Analyst Ratings
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)